Product
WX-0593
Aliases
FL-006, WX-0593 Tablets
3 clinical trials
2 indications
Indication
Lung CancerIndication
NSCLCClinical trial
A Phase II Study to Investigate the Efficacy and Safety of WX-0593 in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) PatientsStatus: Active (not recruiting), Estimated PCD: 2023-07-15
Clinical trial
An Open-label, Randomized, Multicenter Phase 3 Study Comparing WX-0593 to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) PatientsStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer : a Single-arm, Exploratory TrialStatus: Not yet recruiting, Estimated PCD: 2025-03-01